JNJ-61803534

JNJ-61803534 is a potent and orally active RORγt inverse agonist with an IC 50 of 9.6 nM. JNJ-61803534 has anti-inflammatory activity. JNJ-61803534 inhibits IL-17A production in human CD4+ T cells under Th17 differentiation conditions In Vitro JNJ-61803534 inhibits RORγt transcription in HEK-293 T cells transfected with vectors encoding RORγt, with an IC 50 of 9.6 nM. JNJ-61803534 (1 nM-1 μM) inhibits IL-17A, IL-17F IFNγ and IL-22 production in CD4+ T cells isolated from human blood. JNJ-61803534 does not impact in vitro Treg differentiation in CD4+ T cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo JNJ-61803534 (100 mg/kg, p.o.) inhibits ex vivo stimulated IL-17A production in the blood of mice . JNJ-61803534 (3-100 mg/kg BID or 60 mg/kg QD, p.o.) alleviates inflammation, cartilage damage, bone destruction in mouse collagen-induced arthritis (CIA) model . JNJ-61803534 (30 and 100 mg/kg, p.o.) alleviates Imiquimod -induced dermal psoriatic-like inflammation in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mouse collagen-induced arthritis (CIA) model Dosage: 3-100 mg/kg BID or 60 mg/kg QD Administration: Oral administration (p.o.) Result: Decreased clinical arthritis scores and hind paw histopathology scores. Form:Solid IC50& Target:RORγt

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet